Jump to the top of the page

Investment Banking

The Quarterly Rx: Q2 2022 U.S. Biopharma Recap

An increase in M&A and financing activity to end biopharma's Q2 have rekindled hope that we’re finally out of the biotech winter, while others fear it’s just a false spring. As companies continue to weather the storm, the focus remains on cash runway, quality news flow/clinical data, and consolidation. William Blair's Biopharma team shares perspectives in The Quarterly Rx: Q2 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Fortis Has Been Recapitalized by Lovell Minnick and Audax

    William Blair acted as financial advisor to Fortis Payment Systems in connection with its recapitalization by existing investor Lovell Minnick Partners and new investor Audax Group.

    Read more

  • Getting Into (Bi)Specifics

    Explore the latest trends and breakthroughs in bispecific therapies, as our biotechnology equity research team highlights significant growth, recent successes, and market opportunities in this rapidly expanding field.

    Read more

  • Healthcare Mosaic Report: Digital Health Update—No Longer Unicorns, but Phoenixes Abound

    Discover how the digital healthcare marketplace is thriving with robust private market funding, M&A activity, and innovative solutions despite the challenges being faced by publicly traded companies.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures